Amplifying the ADC Advantage: ADCs as the Next Frontier in Precision Lung Cancer Care Published 2023-07-17 Download video MP4 360p Download video MP4 720p Recommendations 27:03 Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference 41:58 Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in NSCLC 1:06:54 Beyond the Horizon in Gastric Cancer: Updated Evidence on How Systemic Therapies Are Redefining Care 56:23 Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and Others 2:16:45 Immuno-Oncology Symposium - Part 1 47:57 Lung Cancer New Treatment 2023 51:40 TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal 1:27:19 The Art of Aging Well 1:01:12 Pioneering Precision Medicine in Bladder Cancer 1:32:40 Drs. Javle, Bekaii-Saab, & Shroff discuss #BiliaryCancer at #GI24 - https://bit.ly/BiliarySF24Y 2:08:42 #140 - Gerald Shulman, MD, PhD: Insulin resistance—molecular mechanisms and clinical implications 01:42 What are Antibody Drug Conjugates (ADCs) 1:28:26 Cancer Metabolism: From molecules to medicine 1:25:11 Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers 04:38 Difference Between Immunotherapy, Targeted Therapy and Chemotherapy 38:07 Antibody-Drug Conjugates (ADCs): Current Research and Overcoming Challenges - Webinar Playback 10:06 Best Foods for Healthy Lungs (Detox and Cleanse) 23:53 Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools 2:02:50 Achieving Next-Level Care in AML 03:09 Highlights on datopotamab deruxtecan in advanced NSCLC: The TROPION-Lung01 study Similar videos 02:26 Exploring antibody-drug conjugates (ADCs) in lung cancer 1:00:30 ADC’s - What Everyone with MBC Should Know about Antibody Drug Conjugates 1:00:29 Answers to Key Questions About Antibody–Drug Conjugates in NSCLC 57:16 Antibody-drug Conjugates in the Clinic: 32:15 A Visual Exploration of New Targeted Therapies for EGFR Exon 20 Insertions in NSCLC 49:11 How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans in Resectable NSCLC 52:28 Taking Direction From Biomarkers and Prognostic Factors in CLL 1:39:25 Drs. Liu, Johnson, Levy, & Peters discuss #NSCLC at #ASCO23 - https://bit.ly/3WI6bL6 5:11:25 Hall B - Day 2, Fortis Cancer Summit 2024 54:28 #LetsTalkNMD Webinar: Anti-sense Oligonucleotide Therapies for Neuromuscular Disorders 55:51 Highlights from ASCO 2023 More results